Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis

Authors

Institutions

Publication Details

Journal
Rheumatology and Therapy
Published
2025-07-05
DOI
https://doi.org/10.1007/s40744-025-00776-4
Primary Topic
Inflammatory mediators and NSAID effects
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis

Subhashis Banerjee, Miroslawa Nowak, June Y. Ye, Atul Deodhar et al.
Rheumatology and Therapy
Inflammatory mediators and NSAID effects
article

Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis

Subhashis Banerjee, Miroslawa Nowak, June Y. Ye, Atul Deodhar, Philip J. Mease, Tom Lehman
article en

Abstract

No abstract available for this paper.
Rheumatology and TherapyVol. 12(5)
Oregon Health & Science University (US), Bristol-Myers Squibb (United States) (US), Swedish Medical Center (US), Bristol-Myers Squibb (Sweden) (SE)
Bristol-Myers Squibb
Good health and well-being
Openalex Percentile: Top 81%
Inflammatory mediators and NSAID effects
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.